PerdanaHealth Nicotine Programme

Public programme brief · Version 0.1 · 2 October 2026

The proposed PerdanaHealth Nicotine Programme is a voluntary, confidential pathway linking behavioural support, qualified clinical or pharmacy assessment, appropriate treatment access and structured follow-up. It is designed for collaboration with clinics, employers and institutional sponsors, rather than as a stand-alone medicine retail service.

Programme scope

The proposed scope covers cigarettes, vaping, heated tobacco and dual use. Malaysia's Nicotine Dependence Management Pharmacy Service Protocol, Third Edition 2026, expands the pharmacy-service scope beyond conventional smoking to include vapes and heated tobacco products (MOH Pharmaceutical Services Programme).

WHO's adult tobacco-cessation guidance addresses behavioural interventions, digital support and pharmacological treatment (WHO clinical treatment guideline, 2024). Its tobacco-treatment recommendations should not be treated as a complete, interchangeable protocol for every vaping population.

Proposed service journey

• Engage: Offer a clear, voluntary invitation with an explanation of confidentiality and available support.
• Assess: A suitably qualified professional assesses product use, dependence, readiness, relevant health history and treatment suitability.
• Plan: Agree an individual support plan, behavioural strategies and any clinically appropriate treatment or referral.
• Support: Arrange consented follow-up, address barriers and provide a route back to the responsible professional.
• Review: Record progress, treatment experience, relapse and the next agreed step without blame.

Medicine selection, prescribing, supply and counselling remain with authorised professionals and organisations. This public brief contains no dosing instructions and is not a self-prescribing tool.

Clinic and employer model

PerdanaHealth's proposed contribution is programme design, onboarding, staff orientation, workflow support and protected aggregate evaluation. The actual care provider and pharmacy arrangements must be specified in a written service agreement before a cohort begins.

Employers should not receive individual clinical notes or identifiable cessation outcomes through routine programme reporting. Participation should be separate from disciplinary processes and unrelated employment decisions.

Evaluation

Proposed measures include invitations and enrolment, engagement, quit attempts, follow-up retention, clinically appropriate treatment uptake and clearly defined cessation outcomes. Reports should state the denominator, product type, follow-up interval and whether outcomes are self-reported or independently verified.

Missing follow-up must remain visible. Vaping and smoking outcomes should not be combined in a way that obscures continued use of another product.

Readiness and enquiries

Institutional service-design enquiries are open. Participant enrolment and treatment delivery follow confirmed provider arrangements, clinical leadership, consent and privacy processes, adverse-event handling and escalation procedures.

Current status: programme development. No treatment cohort, partner appointment or programme-specific effectiveness result is announced in this brief.